Drug Approval | April 20, 2026
Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
The Abbreviated New Drug Application with FDA covers multiple strengths of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
